Save
Treatment of progressive MS with MD1003 (high dose pharmaceutical grade biotin): real-world evidence
Author(s): ,
J. Ciron
Affiliations:
CRC-SEP, Pole des Neurosciences Hopital Pierre Paul Riquet, CHU Toulouse
,
B. Pignolet
Affiliations:
CRC-SEP, Pole des Neurosciences Hopital Pierre Paul Riquet, CHU Toulouse; UMR U1043 Université de Toulouse
,
F. Bucciarelli
Affiliations:
CRC-SEP, Pole des Neurosciences Hopital Pierre Paul Riquet, CHU Toulouse; UMR U1043 Université de Toulouse
,
D. Biotti
Affiliations:
CRC-SEP, Pole des Neurosciences Hopital Pierre Paul Riquet, CHU Toulouse
,
F. Lerebours
Affiliations:
CRC-SEP, Pole des Neurosciences Hopital Pierre Paul Riquet, CHUToulouse
,
G. Dorcet
Affiliations:
CRC-SEP, Pole des Neurosciences Hopital Pierre Paul Riquet, CHU Toulouse; UMR U1043 Université de Toulouse
,
C. Rabadeux
Affiliations:
CRC-SEP, Pole des Neurosciences Hopital Pierre Paul Riquet, CHU Toulouse
,
N. Freitas
Affiliations:
CRC-SEP, Pole des Neurosciences Hopital Pierre Paul Riquet, CHU Toulouse
,
F. Bonneville
Affiliations:
Département de Radiologie, CHU Toulouse, Toulouse, France
D. Brassat
Affiliations:
CRC-SEP, Pole des Neurosciences Hopital Pierre Paul Riquet, CHU Toulouse; UMR U1043 Université de Toulouse
ECTRIMS Online Library. Brassat D. Oct 12, 2018; 229062; P1222
David Brassat
David Brassat
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: P1222

Type: Poster Sessions

Abstract Category: Therapy - Neuroprotection and Repair

Background: In the MS-SPI study, MD1003 (high dose Pharmaceutical grade Biotin)treatment was shown to be effective and well-toleratedin patients (pts) with progressive multiple sclerosis (PMS) (Tourbah et al., 2016). Notably, MD1003 reversed MS-related disease disability in 13% of pts with PMS. MD1003 is currently being prescribed to pts with PMS in France under an expanded access programme.
Objective: To determine the benefits, in terms of effectiveness and safety, of MD1003 in pts with primary PMS (PPMS) or secondary PMS (SPMS) in a real-world clinical centre.
Methods: MD1003 300mg/day (100mg TID) was prescribed to pts with PPMS or SPMS being cared for at a single centre in France (CHU-Toulouse) starting in January 2016.The following measures of effectiveness and safety are being collected: Expanded Disability Status Scale (EDSS), timed 25-foot walk (T25W), 9-hole peg test (9-HPT), number of relapses, and gadolinium (Gd)-enhancing lesions on T1-weighted images.
Results: To date (May 2018), a total of 220 pts have received MD1003; results presented here correspond to the first 91 pts that have 1 year of follow-up. At baseline (month [M] 0), mean age was 59.5 years (SD=9.3), 61.5% were females, 70.3% had SPMS, mean EDSS was 5.9 (SD=1.3), mean TW25 was 50.7 seconds (SD=69.3), 9-HPT in the dominant hand was 35.1 (SD=20.7), and the mean number of previous relapses was 5.1 (SD=4.8). After 1 year of treatment with MD1003, 19 (23%; n=83 with data) pts experienced improvement in EDSS and 15 (23%; n=66 with data) pts experienced ≥20% improvement in T25W. Active disease, a clinically-defined relapse and/or a Gd-enhancing T1 lesion, was observed in 9 (11%; n=79 with data) pts.
Conclusions: MD1003 300mg/day was effective in the treatment of PMS in a real-world clinical setting; at 1 year of treatment, 23% of pts experienced improvement in MS-related disease activity (as measured by EDSS or TW25). MD1003 was also well-tolerated. This real-world study supports the growing body of evidence that MD 1003 is an effective and safe treatment for PMS.
Disclosure: J. Ciron: nothing to disclose., B. Pignolet: nothing to disclose., F. Bucciarelli: nothing to disclose., F. Lerebours: nothing to disclose., G. Dorcet: nothing to disclose., C. Rabadeux: nothing to disclose., N. Freitas: nothing to disclose., F. Bonneville: nothing to disclose., D. Biotti received speaker honoraria from Teva, Merck, Roche, Biogen, Novartis., D. Brassat received research grant from EU FP7, 305477-2012, EU Marie Curie action 2008 (Co I) ABIRISK (co I), French ministery of health -2008 (PHRC), French MS society 2009, 2012, 2017. Lectures, congress invitation, board participation with Bayer, Biogen, Medday, Merck, Novartis, Roche, Sanofi-Genzyme and Teva

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings